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Introduction
Tuberculosis (TB), as an infectious disease is caused 
by Mycobacterium species in humans (Miotto et al. 
2018). The etiological agent of the disease is most often 
Mycobacterium tuberculosis (MTB), and less commonly 
other species in the Mycobacterium tuberculosis com-
plex (MTBC). Mycobacterium species other than these 
species are classified as non-tuberculosis mycobacteria 
(NTMs) (Waters and Ratjen 2016). In recent years, the 
incidence of diseases caused by NTMs has increased 
due to the increasing number of immunosuppressed 
patients (Samli and Ilki 2016).
Members of MTBC are usually transmitted to 
susceptible persons through airborne means such as 
coughing, sneezing, or speaking by patients suffering 
from infectious tuberculosis (Churchyard et al. 2016). 
The successful establishment of an infection in the lungs 
is influenced by various factors such as phagocytosis 
of the bacilli, their intracellular multiplication, latency, 
and active lung infection (Banuls et al. 2015). However, 
there is no clear evidence that NTMs are transmit-
ted from either person to person or from animals to 
people. Therefore, the transmission of NTMs is prob-
ably through individual contacts with the source of 
infection (Churchyard et al. 2016).
Since the treatment of Mycobacterium species 
depends on the correct identification of the isolate, 
mycobacteriological tests that are leading to the identi-
fication are crucial. Methods that include direct micro-
scopic acid-fast bacilli detection (AFB), growth on the 
solid or liquid media, and biochemical tests continue 
to play significant roles in the identification of myco-
bacteria (Kurtoglu et al. 2011).
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A b s t r a c t
Despite advances in diagnosis and treatment, tuberculosis (TB) continues to be one of the essential health problems throughout the world. 
Turkey is considered to be endemic for TB. In this study, we analyzed the distribution of Mycobacterium species, compare the diagnostic 
methods, and susceptibilities to anti-tuberculosis drugs of TB isolates. The aim was to document the current status and to provide a frame 
of reference for future studies. In this study, 278 Mycobacterium species isolated from 7,480 patients between September 2015 and June 
2019 were included. Löwenstein-Jensen medium (LJ) and MGIT 960 were used for the isolation of strains. Susceptibility to 1st-line anti-
tuberculosis drugs was determined. Positivity rates in clinical samples were as follows: 1.4% for direct microscopic acid-fast bacilli (AFB) 
detection, 3.4% for growth on the LJ, and 3.7% for growth on MGIT-960. Two hundred thirty-three isolates were identified as Mycobacte­
rium tuberculosis complex (MTBC) and 45 were non-tuberculous mycobacteria (NTMs). Eleven of the NTMs (24.4%) were Mycobacterium 
fortuitum group isolates, and eight NTMs (17.7%) were Mycobacterium abscessus complex isolates. A number of patients diagnosed with 
tuberculosis peaked twice between the ages of 20–31 and 60–71. A hundred and eighty-two MTBC isolates (78.1%) were susceptible to all 
1st-line anti-tuberculosis drugs, while 51 isolates (21.9%) were resistant to at least one drug tested. The multidrug-resistant tuberculosis rate 
was 13.7% among resistant strains and 3% in all strains. The liquid cultures were better for detection of both MTBC and NTMs isolates. 
The data demonstrate that MTBC continues to be challenge for this country and indicates the need for continued surveillance and full-
spectrum services of mycobacteriology laboratory and infectious diseases.
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Treatment and prophylaxis of tuberculosis dif-
fer from most other bacterial infections. In general, 
patients should receive multiple antibiotic treatments 
for at least 6 to 9  months (Ozmen et al. 2017). The 
World Health Organization (WHO) recommends 
the combined use of 1st-line drugs in the initial treat-
ment of tuberculosis. However, anti-tuberculosis drug 
resistance remains a significant problem. Of the pri-
mary anti-tuberculosis drugs, isolates showing at 
least isoniazid (INH) and rifampin (RIF) resistance 
are defined as Multiple Drug-Resistant Tuberculosis 
(MDR-TB) (WHO 2019).
In this study, we aimed to document Mycobacterium 
species isolated in a large metropolitan tertiary care 
hospital in Turkey. The laboratory procedures used to 
isolate the organisms were also compared. Similarly, the 
resistance rates to the 1st-line anti-tuberculosis drugs 
were determined. The ultimate aim was to compare 
these data with the earlier studies and to provide the 
frame of reference for future studies.
Experimental
Materials and Methods
Ethical approval was provided from the Ethics 
Committee of Medical School, Bezmialem University, 
Istanbul, Turkey (10.09.2019/16–302).
Our facility is a 700-bed academic hospital pro-
viding tertiary health care in Istanbul city centre, and 
7,480 patients with pre-diagnosis of tuberculosis admit-
ted to Bezmialem University Medical Faculty Hospital 
between September 2015 and June 2019 were included 
in the study. Between the dates indicated, 7,480 clini-
cal specimens were sent to the Clinical Microbiology 
Laboratory with a preliminary diagnosis of tuberculo-
sis. Two hundred seventy-eights of these samples were 
positive for Mycobacterium species in at least one of the 
methods studied. Only the first positive isolates from 
the same patient were included in the study.
Homogenization and decontamination of sputum, 
bronchoalveolar lavage (BAL), fasting gastric juice, 
urine, and abscess materials were performed accord-
ing to published guidelines. Sterile body fluids such as 
cerebrospinal fluid (CSF), peritoneal and pleural fluid, 
and tissue samples were tested without decontamina-
tion. N-acetyl-L-cysteine-4% sodium hydroxide-1.47% 
sodium citrate (NALC-NaOH) method was used for 
decontamination and homogenization of the samples. 
Five to ten ml of each clinical sample was mixed with 
an equal volume of NALC-NaOH solution. The mix-
ture was transferred to tubes and vortexed for not more 
than 30 seconds. The tubes containing the mixture were 
allowed to stand at room temperature for 15 minutes. 
Fifty ml of phosphate buffer (0.067 M, pH = 6.8) was 
added to each tube containing the mixture, and the 
tubes were centrifuged at 3,000 g for 15 minutes. The 
resulting precipitates were diluted with 1–2 ml of phos-
phate buffer (pH = 6.8), and smears were prepared from 
these precipitates. The smears were stained by Erlich-
Ziehl-Neelsen (EZN) (GBL Rose Biology Laboratory, 
Istanbul) method and examined microscopically under 
immersion oil.
Isolation of Mycobacterium species. For all the 
samples, both liquid and solid media are used for cul-
ture. Therefore, any isolate growing either on one of 
these media were used in identification studies. In some 
patients, multiple specimens were submitted for culture, 
and multiple cultures were positive for growth. In those 
patients, the very first isolate was used in the study.
For the liquid culture of mycobacteria, a Mycobac­
terium Growth Indicator Tube (BD MGIT-960, BD, 
Sparks, MD, USA) system was utilized, and the pro-
cedure suggested by the manufacturer was followed. 
Briefly, oleic acid-albumin-dextrose-catalase (OAOC) 
was added to the culture medium and as antimicrobial 
agents, polymyxin B (50 U/ml), azlocillin (10 mcg/ml), 
nalidixic acid (20 mcg/ml), trimethoprim antibiotic 
mixture (PANTA, Becton Dickinson, Sparks, MD, USA; 
5.0 mcg/ml), and amphotericin B (5.0 mcg/ml) were 
added. 0.5 ml of the samples from decontaminated clini-
cal mixtures was inoculated into the culture medium, 
and the culture bottles were incubated for six weeks at 
37°C. Samples were considered negative if no growth 
signal was obtained by the end of this incubation period.
Simultaneous cultivation of the samples on solid 
media was carried out on Löwenstein-Jensen (LJ) slants 
(Becton Dickinson, USA). LJ tubes were evaluated 
daily for 42 days, and the cultures were terminated by 
42nd day if no colonies observed. The presence of acid-
resistant bacilli was screened by EZN staining from 
positive cultures.
Identification of Mycobacterium species. When 
MGIT-960 instrument signaled positivity, firstly, an 
EZN stain was performed to screen for AFB, and the 
positive tubes were inoculated on blood agar medium 
(Becton Dickinson, USA) containing 5% sheep blood, 
and the growth was examined to rule out a contami-
nating bacterial species. Samples were also inoculated 
onto the LJ medium for future susceptibility testing. 
After the growth on either solid or liquid media, the 
identification was performed using the MPT64 immu-
nochromatographic test (BD MGIT TBc Identification 
Test, Becton Dickinson, Sparks, USA).
In the study, M. tuberculosis isolates were identified 
at the ‘complex’ level, and no further identification was 
performed, and therefore, isolates were designated as 
M. tuberculosis complex (MTBC). Non-tuberculous 
mycobacteria (NTMs) species were identified by the 
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Turkish Public Health Laboratory through a commer-
cial molecular assay (GenoType Mycobacterium CM, 
Hain Lifescience GmbH, Nehren, Germany).
Antimycobacterial susceptibility tests. The suscep-
tibilities of MTBC strains to isoniazid (INH), Strepto-
mycin (SM), Rifampicin (RIF), and Ethambutol (ETM) 
were investigated. For this aim, a commercial suscepti-
bility test method (BD BACTEC MGIT-960 SIRE) was 
used. The concentrations of the drugs in the testing 
kit were as follows: SM at 1.0 μg/ml, INH at 0.1 μg/ml, 
RIF at 1.0 μg/ml, ETM at 5.0 μg/ml. The definitions of 
the multidrug resistance were that of the commercial 
test kit (BD BACTEC MGIT-960 SIRE).
Study design and statistical analysis. This study 
was conducted as a retrospective clinical study. Data 
analysis was performed using SPSS 20.0 software pack 
(SPSS Inc., USA).
Results
In 278 (3.7%) of 7,480 clinical specimens from 
patients with suspected tuberculosis, one type of 
Mycobacterium species was isolated. Of the patients 
with Mycobacterium species, 123 (44.2%) were female, 
155 (55.8%) were male.
The type of specimens from which MTBC’s were 
isolated was as follows: 198 respiratory tract samples 
(sputum, BAL and tracheal aspirate), 29 tissue speci-
mens (lymph node biopsy, etc.), 22 sterile body fluids 
(pleura, peritoneum, CSF), 11 fasting gastric fluid, 
11 abscesses, and seven urine samples.
In our study, the AFB positivity was 1.4% (104/7,480), 
and the culture positivity (LJ and/or MGIT-960) was 
3.7% (278/7,480) in the clinical samples of patients with 
suspected tuberculosis. The culture positivity was 3.4% 
for LJ (254/7,480) and 3.7% for MGIT-960 (278/7,480). 
The contamination rate in cultures was 9% (675/7,480) 
for LJ and 7% (525/7,480) for MGIT-960. In the study, 
all strains identified as MBTC or NTMs were identified 
as the same species by both methods.
During the study period, PCR assay was performed 
for 24 patients’ samples upon request from the order-
ing clinics. A commercial automated Real-time PCR 
assay (QIAGEN Benelux B.V. The Netherlands) was 
used at a reference laboratory. Out of these 24 samples, 
five (20.8%) were positive. PCR positive samples were 
also positive in liquid (MGIT-960) and solid (LJ) cul-
ture methods as studied in house, but only three were 
positive by AFB. One of the samples negative by PCR 
(19 patients) was positive by the AFB staining, and 17 
out of these 19 specimens were positive on solid media 
(LJ); all 19 were positive in liquid (MGIT-960) culture.
Two hundred thirty-three (MTBC) and 45 (NTMs) 
strains were positive by liquid (MGIT-960) or solid 
(LJ) culture methods. NTMs distribution was as fol-
lows: 11 (24.5%) isolates were of Mycobacterium fortui­
tum group, eight (17.8%) of Mycobacterium abscessus 
complex, five (11.1%) of Mycobacterium simiae, five 
(11.1%) of Mycobacterium lentifilavum, four (8.9%) of 
Mycobacterium chelonae, four (8.9%) of Mycobacterium 
intracellulare, three (6.7%) of Mycobacterium gordonae, 
two (4.4%) of Mycobacterium avium spp., two (4.4%) of 
Mycobacterium kansasii, and one (2.2%) of Mycobacte­
rium heckeshornense.
The most MTBC isolates were from respiratory spec-
imens; 120 from sputum, 35 from BALs, and four from 
tracheal aspirates. The remaining MTBC were recovered 
from different specimen types. Of the total 45 isolated 
NTMs strains, 37 were isolated from sputum samples. 
The number and the types of specimens from which 
mycobacteria were isolated are presented in Table I.
In the study, the AFB was observed in 98 respiratory 
patient samples. We performed AFS for the patient res-
piratory samples as well as the growing microorganisms 
in the culture. However, 198 respiratory samples grew 
Mycobacterium species that were confirmed as acid-fast 
organisms by staining.
In all 104 patients, the AFB positive samples (res-
piratory, tissue, sterile body fluid), at least one type 
of Mycobacterium species was isolated on either solid 
or in liquid culture methods. Sixty-six (63.5%) of the 
AFB positive samples were obtained from male sub-
jects, 38 (36.5%) were from females, and the mean age 
was 43.16 years old (females, mean age 37.55, males 
– 46.4 years old).
When the age distribution of the patients was 
examined, a bi-modal distribution was observed. The 
Respiratory 198 98 159 39
  Sputum 157 89 120 37
  Bronchoalveolar lavage 37 7 35 2
  Tracheal aspirate  4 2 4 –
Tissue 22 3 21 1
  Lymph Node Biopsy 12 2 12 –
  Other Tissues 10 1 9 1
Sterile body fluid 22 – 22 –
  Pleura 13 – 13 –
  BOS 6 – 6 –
  Peritoneum 3 – 3 –
Abscess  18 3 17 1
Fasting gastric fluid 11 – 9 2
Urine 7 – 5 2
Total 278 104 233 45
Table I
Number, species, AFB positivity and distribution of Mycobacterial 
strains according to clinical samples.
AFB MTBC NTMs
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number of patients diagnosed with tuberculosis peaked 
twice between the ages of 20–31 and 60–71. Similarly, 
isolations of MTBC peaked twice in the patients of 
20–31 and 60–71  age range. The isolation of NTMs 
species was also prominent in the 0–11 age range. The 
distribution of Mycobacterial strains according to age 
groups is presented in Fig. 1.
Of the 233 MTBC strains isolated in the study, 
182 (78.1%) were susceptible to all 1st-line anti-tuber-
culosis drugs, while 51 isolates (21.9%) were resistant to 
at least one of the 1st-line anti-tuberculosis drugs tested 
(Table  II). Total drug resistance rates for INH, SM, 
RIF, and ETM were 16.7% (n = 39), 14.6% (n = 34), 3% 
(n = 7), and 0.8% (n = 2), respectively. The highest rates 
of resistance were observed to the pair of INH + SM 
(n:  22, 9.4%), and the highest rates of resistance to 
three drugs were against INH + SM + RIF (n = 73%). 
Seven rifampin-resistant strains were also resistant to 
INH and SM. One of the strains was resistant to four 
1st-line anti-tuberculosis drugs. In our study, the rate of 
MDR-TB was 13.7% (7/51) among resistant strains and 
3% (7/233) among all strains isolated.
In the present study, 21.4% of MTBC isolates in 
2015, 6.7% in 2016, 25.8% in 2017, 21.8% in 2017, 
36.7% in 2018, and 36.7% in 2017 were tested against 
1st-line anti-tuberculosis drugs. As the number of 
strains isolated in 2017 and 2018 increased, so did 
the number of resistant strains. However, this increase 
was not statistically significant (p < 0.05). The number 
and ratio of isolated resistant MTBC strains by years 
are presented in Table II.
The number of M. tuberculosis isolates at different 
age groups was presented in Fig. 1. Accordingly, the 
numbers of TB isolated at different age groups dem-
onstrated a bi-model distribution peaking at third and 
seventh decade of life. Possible differences between 
various age groups were analyzed by the Chi-square 
test, and in both decades, the rates of M. tuberculosis 
isolations were significantly different.
Discussion
TB remains a major public health problem through-
out the world. According to the 2018 report of the 
World Health Organization, it was estimated that 
in 2017 approximately 10 million people suffered from 
TB, and approximately 1.5 million people have died 
(WHO 2019). The determination of the presence of the 
etiological agent and correct identifications are impor-
tant to prevent the spread of tuberculosis. Therefore, 
it is necessary to isolate, determine the type, and to 
Fig. 1. Distribution of Mycobacterial strains according
to age groups.
 1–10 7 8 15
11–20 37 2 39
21–30 46 6 52
31–40 34 3 37
41–50 10 1 11
51–60 29 5 34
61–70 36 11 47
71–80 22 6 28
 > 81 12 3 15
Age range MTC NTM Total
p < 0.05
Sensitive to all drugs 11 42 49 61 19 182 (78.1)
INH 2 3 13 12 9 39 (16.7)
SM 2 1 11 12 8 34 (14.6)
RIF 1 – 2 2 2 7  (3)
EMB – – – 1 1 2  (0.8)
İNH + SM 2 1 8 7 5 23  (9.9)
INH + RIF + SM (MDR-TB) 1  2 2 2 7  (3)
Table II
Number and proportion of resistant MTBC strains by years.












(n : 233, %)
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assess the drug resistance of Mycobacterium species 
(Kurtoglu et al. 2011).
Direct microscopic examination of smears is rapid 
and relatively practical and, therefore, is preferred 
despite low rates of sensitivity in detecting bacilli 
(Kurtoglu et al. 2011). Patients positive on direct micro-
scopic examination are considered to be both more 
contagious and exhibit a fast progression to clinical dis-
ease. Consequently, a direct microscopic examination 
is recommended, especially in patients with pulmonary 
tuberculosis (Tarylan et al. 2015).
In our study, the AFB positivity was 1.4% (104/7,480), 
and culture positivity (LJ and/or MGIT-960) was 3.7% 
(278/7,480) in patients with suspected tuberculosis. 
Overall, MTBC detection rate was 3.1% (233/7,480). 
Similarly, MTBC detection rate was between 2.1% and 
11% in many studies (Baylan et al. 2002; Dundar et al. 
2009; Kurtoglu et al. 2011).
Today, culture is the standard gold method for the 
detection of mycobacteria (Kunduracioglu et al. 2013). 
World Health Organization recommends the use of 
liquid media for M. tuberculosis culture (WHO 2007). 
In other studies, it has been reported that the liquid 
medium was superior in recovering mycobacteria over 
solid media (Hwang et al. 2014; Kwak et al. 2017). In 
the current investigation, mycobacteria were detected 
in 3.7% (278/7,480) liquid cultures (MGIT-960) and 
3.4% (254/7,480) solid (LJ) cultures.
Age distribution of TB patients is an important 
parameter reflecting the control of TB in the commu-
nity. While the disease peaks in advanced ages in popu-
lations that implement effective TB control programs, 
in populations where the control programs are lax, the 
disease peaks at younger ages (Karatas et al. 2019). In 
some studies, the TB is seen mostly in advanced ages 
(Coffman et al. 2017); however, in an earlier Turkish 
study (Karatas et al. 2019), it was reported two peaks 
of the TB prevalence in the age group 15–24 and over 
65 years old. Similarly, we noticed that the number 
of patients diagnosed with tuberculosis peaked twice 
between the ages of 20–31 and 60–71 years. These 
results suggest that the Turkish population is composed 
of mixed communities where both loose and effective 
TB control efforts are exerted.
The isolation rate of mycobacteria (NTMs) other 
than the M. tuberculosis complex is increasing through-
out the world (Mbeha et al. 2014). To date, more than 
160 NTMs species have been identified, and approxi-
mately one third is associated with diseases in humans. 
It has been shown to cause serious clinical conse-
quences, especially in people with immunodeficiency 
(Liu et al. 2016). It has been reported that the distribu-
tion of NTMs species varies according to geographical 
regions and demographic characteristics of affected 
patients (Spaulding et al. 2017).
In our study, NTMs were isolated from 45 patients. 
Among NTMs, M. fortuitum group (11  isolates), and 
M. abscessus complex (eight isolates) were the most 
common mycobacteria. In the US study, Spaulding 
et al. (Spaulding et al. 2017) reported that other than 
MAC, M. abscessus/M. chelonae, and M. fortuitum were 
the most common isolated NTMs species. In other 
investigations, the frequencies among NTMs species 
varied significantly according to geographical regions. 
In a study conducted in China, Liu et al. (2016) found 
that more than half (59.66%) of 523 NTMs isolates 
were M. avium, and M. intracellulare. In this study, 
rapid growers such as M. abscessus and M. fortuitum 
were more frequent. The number MAC isolates were 
not as high as the others (Liu et al. 2016; Spaulding 
et al. 2017). Many factors could be accounted for this 
difference. The discrepancies in the number of peo-
ple with immunodeficiency could be one factor since 
immunodeficiency seems to be an underlying risk 
factor for MAC infection. TB is a disease that should 
be treated with proper drug regimens to be admin-
istered to patients. The increased drug resistance 
complicates the treatment and impairs control of the 
disease. In many studies, resistance rates to com-
monly used 1st-line anti-tuberculosis drugs have been 
reported to be between 10–25% for INH, 3–16% for 
RIF, 0.7–19% for SM, and 0.7–10% for ETM (Karadag 
et al. 2004; Saral et al. 2007; Dundar et al. 2009; Aydin 
et al. 2011; Perincek et al. 2011). Similarly, in this 
report, resistances to 1st-line anti-tuberculosis drugs of 
INH, SM, RIF and ETM were 16.7%, 14.6%, 3%, and 
0.8%, respectively. These data argue that the rate of 
resistance in this country follows trends not unlike 
those of other countries.
In many studies, it has been reported that resist-
ance to INH and RIF are often, but resistance to other 
anti-tuberculosis drugs may also develop (Dheda et al. 
2014; Pienar et al. 2018). However, in some studies, 
similar to our study, resistance to INH and SM was 
higher, and RIF and ETM resistances were reduced. In 
these studies, there were significant differences between 
the resistance rates by region, and the primary anti-
tuberculosis drugs with the highest resistance rates 
were INH and SM (Kurtoglu et al. 2011; Linger et al. 
2014; Sani et al. 2015; Stagg et al. 2017). It is thought 
that higher rates of INH and SM resistance compared 
to other primary anti-tuberculosis drugs may be related 
to the more frequent use of these drugs in both prophy-
laxis and treatment. Similar arguments could be put 
forth for this country.
The Report of the Turkish Association of Anti-TB 
Campaign published in 2018 indicated that in 2016, 
the drug susceptibility test results were surveyed for 
6,037  MTC, and resistance to at least one drug was 
detected in 19.2% isolates. According to this report, 
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3.3% of the patients who underwent drug susceptibil-
ity testing were found to have MDR-TB, and the rate 
of multidrug resistance was 2.1% in new patients and 
14.2% in previously treated patients (Saglik Bakanligi 
T.C. 2018). According to WHO 2018 data, MDR-TB 
ratio is 3.5% of new TB cases and 18% of previously 
treated cases globally (WHO 2019). The rates of MDR-
TB in the studies made in different regions of Turkey 
vary between 2.2–14.7% (Saral et al. 2007; Dundar et al. 
2009; Aydin et al. 2011; Kurtoglu et al. 2011). In our 
study, resistance to more than one drug was detected in 
51 (21.88%) isolates. MDR-TB ratio was 13.7% (7/51) 
among resistant strains and 3% (7/233) among all strains 
isolated, and this rate was consistent with other studies.
Today, the number of patients with tuberculosis has 
increased, possibly due to changes in recent years such 
as social and economic turmoil, increased number of 
migrant patients, changes in the practices healthcare 
system, and drug-resistant Mycobacterium isolates. 
Therefore, a correct and rapid diagnosis and supervised 
treatment concepts should be reviewed and applied to 
prevent susceptible strains from gaining resistance and 
stopping the further spread of resistant strains. Our 
data indicate that NTMs species will probably be more 
frequently encountered in the future. Furthermore, we 
can speculate that drug resistance will continue to be an 
important problem in patients with tuberculosis.
One of the limitations of this study was that the 
patients and the isolates were selected from a single cen-
tre albeit it was a large tertiary care centre. This might 
have influenced the information gathered. However, it 
should also be stated that the medical centre where the 
study is conducted is located in the heart of the old city 
of Istanbul, where the immigrants are concentrated.
Data from this study indicate that the frequency 
of isolations of M. tuberculosis complex in the popu-
lation seems to form a bimodal distribution, one in 
the third decade of life and the other in the 7th. Obvi-
ously, our study is not designed to address this par-
ticular demographic aspect of M. tuberculosis infection 
in detail. However, we judge that providing such data 
would be a useful addition to a study aiming to cap-
ture a current picture of Mycobacterium species in an 
endemic country.
In conclusion, this investigation demonstrates that 
tuberculosis is still a growing public health threat in 
Istanbul, Turkey. We do not know how much of this 
increase is the result of the recent high immigration 
rates. The drug resistance rates also seem to be on the 
rise. Therefore, rapid and accurate laboratory services 
are imperative in combatting such a growing pub-
lic health menace. Our study demonstrates that the 
liquid culture is superior to the solid media for the 
recovery of Mycobacterium species and, hence, should 
be included in the routine mycobacteriology laboratory 
procedures. Collectively, these results underscore the 
need for the marshaling preventive public health efforts 
on this age-old concern.
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